Deal summary reprinted from Strategic Transactions - April 2009
Orthocon (absorbable products for orthopedic and spine surgeries) raised $25mm in its Series B financing that was co-led by ProQuest Investments and Canaan Partners with additional funds coming from returning shareholder BB Biotech Ventures.
Orthocon closes $25mm Series B round
Deal summary reprinted from Strategic Transactions - April 2009
Founded in 2005, Orthocon is creating implantable devices designed to deliver various therapeutics to bone. Its lead product candidate is an extended-release local anesthetic bone hemostat that stops bleeding and locally relieves pain. Clinical trials are slated to begin later this year. The company recently announced that Paul Sohmer, MD, is taking over as president and CEO. He will also join the board along with a representative from ProQuest. To date Orthocon has raised $35mm in VC money.
About Strategic Transactions - The Device Deal Database
Our proprietary database is designed for medical technology professionals and investors that need to stay current on the latest industry alliances, financing, mergers & acquistions and other strategic partnerships.
Find out more about what our Strategic Transactions - The Device Deal Database can do for you.
Strategic Transactions - The Device Deal Database provides expanded information, including:
- Comprehensive Deal Records
- Complete Financial Information
- Extensive Company Profiles
- Access to important SEC Documents
- Links to related articles
Contact: James DeFalco at: +1 (203) 838-4401 x104 or jdefalco@windhover.com.
